Skip to main content

Advertisement

Log in

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

  • PHASE I STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose This open-labeled, phase I clinical trial was designed to determine the safety and tolerability of percutaneous intralesional administration of wild-type oncolytic revovirus type 3 Dearing (Reolysin®) in cancer patients with accessible and evaluable disease, who had otherwise failed to improve on standard cancer interventions. Experimental Design An escalating dose of Reolysin® starting from up to 1010 plague forming units (PFU) was administered to each cohort of three patients per dose level. Viral shedding, reovirus neutralizing antibody response, toxicity and clinical response were assessed. Results Nineteen patients with various advanced solid tumors were treated. The most common toxicities related to treatment were grade 2 (or less) local erythema and transient flu like symptoms. Viral shedding was not seen in cerebral spinal fluid (CSF), urine and stool samples in all patients. Rising viral antibody titres were seen in all patients. In addition, we observed some evidence of local target tumor response activity in 7/19 patients (37 %) at the end of six or more weeks follow-up, with one patient exhibiting a complete response (CR), two a partial response (PR), and four stable disease (SD) to the local injected lesion. Conclusions Reolysin® is well tolerated given intralesionaly, with DLT/MTD not reached at a dose of 1010 PFU. The favorable toxicity profile, lack of viral shedding and possible therapeutic activity has made this unattenuated oncolytic reovirus an attractive cancer therapeutic agent for ongoing clinical studies, including in the setting of locally advanced accessible disease for palliation of symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dock G (1904) Rabies virus vaccintion in a patient with cervical carcinoma. Amer J Med Sci 127:563

    Google Scholar 

  2. Deweese TL, Van Der Poel H, Li SD, Mikhak B, Drew R, Goemann M, Hamper U, Dejong R, Detorie N, Rodriguez R, Haulk T, Demarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW (2001) A phase I trial of Cv706, a replication-competent, Psa selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation Therapy. Cancer Res 61:7464–7472

    PubMed  CAS  Google Scholar 

  3. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O’neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM (2002) Phase I trial of intravenous administration of Pv701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20:2251–2266

    Article  PubMed  CAS  Google Scholar 

  4. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O’neill V, Siddiqui N, Seiden MV, Kaye SB (2002) Phase I trial of intraperitoneal injection of the E1b-55-Kd-Gene—deleted adenovirus Onyx-015 (Dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20:1562–1569

    Article  PubMed  CAS  Google Scholar 

  5. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1b-attenuated adenovirus, Onyx-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958–966

    Article  PubMed  CAS  Google Scholar 

  6. Reid TR, Freeman S, Post L, Mccormick F, Sze DY (2005) Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-Fu/Leucovorin. Cancer Gene Therapy 12:673–681

    Article  PubMed  CAS  Google Scholar 

  7. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T (2006) Phase I/Ii trial of intravenous Ndv-huj oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221–228

    Article  PubMed  CAS  Google Scholar 

  8. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O’neil JD, Roberts MS, Groene WS, Lorence RM (2006) A phase I clinical study of intravenous administration of Pv701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12:2555–2562

    Article  PubMed  CAS  Google Scholar 

  9. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata KI, Ren CZ, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D (2011) Glipr1 tumor suppressor gene expressed by adenoviral vector as Neoadjuvant Intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174–7182

    Article  PubMed  CAS  Google Scholar 

  10. Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH (2011) A mechanistic proof-of-concept clinical trial with Jx-594, a targeted multi-mechanistic Oncolytic Poxvirus, in patients with metastatic melanoma. Mol Ther 19:1913–1922

    Article  PubMed  CAS  Google Scholar 

  11. Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, Shikano T, Nomoto S, Takeda S, Kodera Y, Nishiyama Y (2011) A phase I dose-escalation clinical trial of Intraoperative direct Intratumoral injection of Hf10 Oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Therapy 18:167–175

    Article  PubMed  CAS  Google Scholar 

  12. Parato KA, Senger D, Forsyth PAJ, Bell JC (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5:965–976

    Article  PubMed  CAS  Google Scholar 

  13. Rosen L, Spickard A, Evans HE (1963) Reovirus infections in human volunteers. American Journal Hygiene 77:29

    CAS  Google Scholar 

  14. Jackson GG, Muldoon RL (1973) Viruses causing common respiratory-infection in Man.4. Reoviruses and adenoviruses. J Infect Dis 128:811–866

    Article  PubMed  CAS  Google Scholar 

  15. Coffey MC, Strong JE, Forsyth PA, Lee PWK (1998) Reovirus therapy of tumors with activated ras pathway. Science 282:1332–1334

    Article  PubMed  CAS  Google Scholar 

  16. Bos JL (1989) Ras oncogenes in human cancer—a review. Cancer Res 49:4682–4689

    PubMed  CAS  Google Scholar 

  17. Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M (2009) Reovirus-based therapy for cancer. Expert Opin Biol Ther 9:817–830

    Article  PubMed  CAS  Google Scholar 

  18. Strong JE, Lee PWK (1996) The V-Erbb Oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70:612–616

    PubMed  CAS  Google Scholar 

  19. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PWK (1998) The molecular basis of viral oncolysis: Usurpation of the ras signaling pathway by reovirus. EMBO J 17:3351–3362

    Article  PubMed  CAS  Google Scholar 

  20. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PWK (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15:1522–1530

    Article  PubMed  CAS  Google Scholar 

  21. Clarke P, Meintzer SM, Wang YB, Moffitt LA, Richardson-Burns SM, Johnson GL, Tyler KL (2004) Jnk regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. J Virol 78:13132–13138

    Article  PubMed  CAS  Google Scholar 

  22. Connolly JL, Rodgers SE, Clarke P, Ballard DW, Kerr LD, Tyler KL, Dermody TS (2000) Reovirus-induced apoptosis requires activation of transcription factor Nf-Kappa B. J Virol 74:2981–2989

    Article  PubMed  CAS  Google Scholar 

  23. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PWK, Kossakowska AE (2002) Reovirus therapy of lymphoid malignancies. Blood 100:4146–4153

    Article  PubMed  CAS  Google Scholar 

  24. Hanel EG, Xiao ZW, Wong KK, Lee PWK, Britten RA, Moore RB (2004) A novel intravesical therapy for superficial bladder cancer in an orthotopic model: Oncolytic reovirus therapy. J Urol 172:2018–2022

    Article  PubMed  CAS  Google Scholar 

  25. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PWK (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62:1696–1701

    PubMed  CAS  Google Scholar 

  26. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, Difrancesco LM, Strong JE, Lee PWK (2002) Reovirus oncolysis of human breast cancer. Human Gene Therapy 13:641–652

    Article  PubMed  CAS  Google Scholar 

  27. Wilcox ME, Yang WQ, Senger D, Rewcastle NB, Morris DG, Brasher PMA, Shi ZQ, Johnston RN, Nishikawa S, Lee PWK, Forsyth PA (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. Journal National Cancer Institute 93:903–912

    Article  CAS  Google Scholar 

  28. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, Debono JS (2008) A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res 14:7127–7137

    Article  PubMed  CAS  Google Scholar 

  29. Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S (2010) Intravenous administration of reolysina (R), A live replication competent Rna virus is safe in patients with advanced solid tumors. Investigational New Drugs 28:641–649

    Article  PubMed  Google Scholar 

  30. Galanis E, Markovic SN, Suman V, Nuovo G, Vile R, Coffey M, Linette G, Maples W, Zwiebel J, Kendra K (2011) Phase II trial of intravenous administration of Reolysin (Reovirus Serotype-3-Dearing Strain) in patients with metastatic melanoma. Mol Ther 19:1375

    Google Scholar 

  31. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS (2010) Reo-10: A Phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16:5564–5572

    Article  PubMed  CAS  Google Scholar 

  32. Karapanagiotou E, Pandha HS, Hall G, Chester J, Melcher A, Coffey M, De Bono J, Gore Me, Nutting CM, Harrington KJ (2009) Phase I/Ii trial of oncolytic reovirus (Reolysin) in combination with Carboplatin/Paclitaxel in patients (Pts) with advanced solid cancers. J Clinical Oncology 27

  33. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey M, Mettinger K, Gill G, Evans TRJ, De Bono JS (2011) A phase I study of the combination of intravenous reovirus type 3 dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17:581–588

    Article  PubMed  CAS  Google Scholar 

  34. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B, Hamilton M (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16:627–632

    Article  PubMed  CAS  Google Scholar 

  35. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA (2010) Two-stage phase I Dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16:3067–3077

    Article  PubMed  CAS  Google Scholar 

  36. Clayman GL, El Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H (1998) Adenovirus-mediated P53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221–2232

    PubMed  CAS  Google Scholar 

  37. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owenschaub LB, Roth JA (1994) Induction of chemosensitivity in human lung-cancer cells in-vivo by adenovirus-mediated transfer of the wild-type P53 gene. Cancer Res 54:2287–2291

    PubMed  CAS  Google Scholar 

  38. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated P53 gene transfer. J Thorac Cardiovasc Surg 112:1372–1376

    Article  PubMed  CAS  Google Scholar 

  39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. Journal National Cancer Institute 92:205–216

    Article  CAS  Google Scholar 

  40. White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing Type 3) during a phase i clinical trial. Gene Therapy 15:911–920

    Article  PubMed  CAS  Google Scholar 

  41. Qiao J, Wang HX, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, De Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K (2008) Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14:259–269

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank all our participating patients, our research nurses and coordinators in TBCC. This work is funded by Oncolytics Biotech Inc. and Alberta Cancer Board.

Disclosure of potential conflicts of interest

M. Coffey and B. Thompson are employed by Oncolytics Biotech Inc and they both have an ownership interest in that company; D. Morris and P. Forsyth has received research grants from Oncolytics Biotech Inc.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Don G. Morris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, D.G., Feng, X., DiFrancesco, L.M. et al. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 31, 696–706 (2013). https://doi.org/10.1007/s10637-012-9865-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-012-9865-z

Keywords

Navigation